公开(公告)号：US20170015655A1

公开(公告)日：2017-01-19

申请号：US15210965

申请日：2016-07-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Akira KAIEDA ,  Masashi TOYOFUKU ,  Masaki DAINI ,  Hiroshi NARA ,  Masato YOSHIKAWA ,  Naoki ISHII ,  Kousuke HIDAKA

IPC: C07D413/14 ,  C07D417/14 ,  C07D491/08 ,  C07D491/107 ,  C07D413/04 ,  C07D471/04

CPC classification number: C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D491/08 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US20150353578A1

公开(公告)日：2015-12-10

申请号：US14804935

申请日：2015-07-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体 增效作用 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US20140080817A1

公开(公告)日：2014-03-20

申请号：US13774707

申请日：2013-02-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体 增效作用 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US20130184266A1

公开(公告)日：2013-07-18

申请号：US13774635

申请日：2013-02-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20230322683A1

公开(公告)日：2023-10-12

申请号：US17766400

申请日：2020-10-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masashi TOYOFUKU ,  Yoshiteru ITO ,  Marilena PIRA ,  Takahiro SUGIMOTO

IPC: C07D231/56 ,  C07D405/12 ,  C07D471/04 ,  C07D498/04 ,  A61P25/28

CPC classification number: C07D231/56 ,  C07D405/12 ,  C07D471/04 ,  C07D498/04 ,  A61P25/28

Abstract: The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20200317692A1

公开(公告)日：2020-10-08

申请号：US16827316

申请日：2020-03-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20190008836A1

公开(公告)日：2019-01-10

申请号：US15745290

申请日：2016-07-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Akira KAIEDA ,  Masaki DAINI ,  Hiroshi NARA ,  Masato YOSHIKAWA ,  Naoki ISHII ,  Masashi TOYOFUKU ,  Kousuke HIDAKA

IPC: A61K31/437 ,  A61P25/28 ,  A61K31/4245 ,  A61K31/4035 ,  A61K31/4439

CPC classification number: A61K31/437 ,  A61K31/4035 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61P25/28 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20180162875A1

公开(公告)日：2018-06-14

申请号：US15845621

申请日：2017-12-18

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20180162853A1

公开(公告)日：2018-06-14

申请号：US15882386

申请日：2018-01-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/14 ,  C07D333/38 ,  C07D413/14 ,  C07D407/12 ,  C07D307/79 ,  C07D409/12 ,  C07D417/12 ,  C07D307/81 ,  C07D413/12 ,  C07D409/14 ,  C07D231/12 ,  C07D277/56 ,  C07D285/135 ,  C07D285/08 ,  C07D333/40 ,  C07D231/14 ,  C07D213/82

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US20170029417A1

公开(公告)日：2017-02-02

申请号：US15302405

申请日：2015-04-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/14 ,  C07D231/14 ,  C07D285/135 ,  C07D413/14 ,  C07D307/81 ,  C07D407/12 ,  C07D213/82 ,  C07D333/38 ,  C07D417/12 ,  C07D409/12

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 本发明提供具有赖氨酸特异性脱甲基酶-1抑制作用的化合物，可用作精神分裂症，发育障碍，特别是具有智力障碍的疾病（例如自闭症谱系，Rett综合征， 唐氏综合征，歌舞伎综合征，脆性X综合征，克莱斯特综合征，1型神经纤维瘤病，Noonan综合征，结节性硬化症），神经变性疾病（如阿尔茨海默氏病，帕金森病，脊髓小脑变性（例如，牙周性苍白球萎缩症）和亨廷顿疾病）），癫痫 （例如，Dravet综合征）或药物依赖性等。 由下式表示的化合物，其中每个符号如本说明书中所定义，或其盐。